Teva's Copaxone sales see 12% spike; Vertex ups Kalydeco revenue guidance;

@FiercePharma: VCA ups 2015 guidance as 2Q sales and profits soar past expectations. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: As #Hospira expands recall of #ketorolac to 37M vials you've got to wonder what Pfizer thinks. Story | Follow @EricPFierce

@CarlyHFierce: Here's our latest at @FierceBiotech radio. I haven't listened to it yet, but someone told me it was good. Listen | Follow @CarlyHFierce

> Teva's ($TEVA) Copaxone sales rose 12% in Q2 despite new generic competition from Novartis' ($NVS) Glatopa. Report

> Vertex ($VRTX) upped its guidance for Kalydeco net revenue, now expecting $575 to $590 million for the year. Release

> India's Delhi High Court has dismissed a plea from AstraZeneca ($AZN) to block copies of diabetes drug Onglyza; the patent office will now decide whether to grant a compulsory license for the treatment. Report

> Alexion ($ALXN) hiked its revenue guidance to between $2.6 billion and $2.62 billion, up from a $2.55 billion to $2.6 billion range. Report

> The U.S. Senate Thursday used Valeant ($VRX) to lay out how U.S. tax laws have created an uneven playing field for some of America's largest companies. More

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA approves first weight-loss balloon, giving the obese a minimally invasive option. Article | Follow @FierceMedDev

@VarunSaxena2: FDA clears devices to reduce snoring in patients without sleep apnea. Report | Follow @VarunSaxena2

@EmilyWFierce: Indian diagnostics outfit debuts 'lab-on-cartridge' device for developing countries. More | Follow @EmilyWFierce

> In a big week for obesity devices, GI Dynamics terminates U.S. pivotal obesity device trial. More

> NeuWave Medical gets FDA clearance for software upgrade to its ablation system. News

Biotech News

@FierceBiotech: FierceBiotech Radio on Allergan's change in tune, Sanofi's new bet on Regeneron, and the latest big biotech IPO. Listen/Subscribe | Follow @FierceBiotech

@JohnCFierce: These Afrezza sales numbers say A: Afrezza isn't winning over many people and B: spurring any patient migrations in diabetes will be tough. | Follow @JohnCFierce

> Synergy Pharma jumps as second PhIII scores a success against constipation. More

> GlaxoSmithKline CEO's enthusiasm for R&D effort falls flat. Article

Vaccines News

> Pfizer's U.S. Prevnar 13 sales jump 87% in Q2. Report

> GSK envisions 'thoughtful, staged rollout' for Mosquirix. More

> Sanofi's dengue vax protects two-thirds of people aged 9 and up: NEJM. Story

> NIH's MERS vaccine looks promising in mice. Item

> Bavarian Nordic starts PhII of Prostvac in early-stage cancer. Article

CRO News

> Charles River's revenue slips on slumping R&D demand. More

> Covance names a new CEO as it adjusts to life with LabCorp. Story

> Patheon unloads some assets on the way to an IPO. Item

> PRA boosts its profit forecast after a strong sales quarter. Report

> Quintiles restores its rosy outlook after a big quarter. Article

Pharma Manufacturing News

> More cuts as Sun Pharma pulls Ranbaxy into the fold. Item

> Cardinal reports rising revenues and says next year looks even better. More

> McKesson reports higher Q1 revenues, but international sales were flat. Report

> FDA issues draft guidance on quality manufacturing metrics. Story

> Regulators in Europe propose bans on plants in China and India. Article

Pharma Asia News

> Is Asia's IP landscape in for big changes under TPP? Item

> India drugs watchdog to look at feasibility of online drug sales. More

> Syngene IPO by India's Biocon reaches top of range with no GVK, Quest blowback. Story

> More change ahead for Novogen as interim CEO Ross orders wide review of programs. Article

> S. Korea's Hanmi sells lung cancer candidate rights to BI in second major deal this year. Report

And Finally... Companies including Pfizer ($PFE) and Teva ($TEVA) are recruiting thousands of recreational drug users for trials of abuse-deterrent opioid candidates. More

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.